Real-World data could unlock better breast cancer treatment choices
NCT ID NCT07647042
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at medical records from 750 people with a common type of early breast cancer (HR+/HER2-). It aims to understand how doctors treat these patients in real life, especially after newer targeted drugs called CDK4/6 inhibitors became available. By analyzing treatment patterns, genetic testing use, and patient outcomes, the study hopes to improve care for future patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this study could reveal how well new targeted therapies work in everyday practice, helping doctors choose the best treatments for early breast cancer.
What could go wrong
This is an observational study using existing medical records, so it cannot prove cause and effect. Results may be limited by incomplete data or differences in patient care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis
East Hanover, New Jersey, 07936, United States